Additionally, AChR-MG subjects showed higher expression FCRL5 in CD11c+ B cells compared to controls and rituximab-naive MuSK-MG patients, demonstrating that these cells may have higher activation rate as overexpression interferes with anergy of the cell (24)(Figure 5E). This evidence concerns the gene FCRL5 and myasthenia gravis.